Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05781113 · ClinicalTrials.gov registry record
A Novel Wearable Digital Biomarker for Detecting Changes in Multiple Sclerosis (MS) Condition
A clinical trial of Multiple Sclerosis, sponsored by Celestra Health Systems.
- Active
- Registry status
- 90
- Enrollment target
- 3
- Study locations
NCT05781113: Active study of Multiple Sclerosis, sponsored by Celestra Health Systems.
NCT05781113 is a study of Multiple Sclerosis that is active but no longer recruiting, run by Celestra Health Systems. The registered enrollment target is 90 participants, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (85% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05781113, a study of Multiple Sclerosis, is active but no longer recruiting, sponsored by Celestra Health Systems.
- ACTIVE NOT RECRUITING
- Registry status
- 90 participants
- Enrollment target
- 3
- Study locations
Study Summary
To measure the effectiveness of a Remote Patient Monitoring solution based on the use of a smart insole wearable device (and associated smart phone app), for monitoring MS patients' condition on a day-to-day basis. The main focus is the objective measurement of gait, given that 75% of people with MS display clinically significant gait impairments. Initial gait lab "gold standard" data indicate that the Artificial Intelligence (AI)-based digital biomarker will prove to be highly effective at detecting changes in the MS patient's condition.
Primary Outcome
To measure participant adherence, with respect to the wearable smart insoles and the associated smart phone app, for the purpose of MS disease monitoring. Adherence is defined as the collection by the participant of 15-minute walking samples 3x per week using the smart insoles and the associated smart phone app. Adherence will be assessed by calculating the number of tasks completed divided by the number of tasks prompted. \> 80% is deemed high adherence.
Conditions Studied
Study Locations (3)
Massachusetts
- Brigham and Women's Hospital - Boston
Ontario
- The Ottawa Hospital - Ottawa
Other
- The Royal London Hospital - London
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2023-07-01 |
| Est. Completion | 2026-12-31 |
What the registry record for NCT05781113 still lists
NCT05781113 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (85% lower).
The record links to 1 condition, with Multiple Sclerosis appearing as the primary indexed condition, and to 0 interventions.
NCT05781113 reports a single indexed study location in Massachusetts, Ontario, Other.
Frequently Asked Questions
What is clinical trial NCT05781113 about?
NCT05781113 is a clinical study titled "A Novel Wearable Digital Biomarker for Detecting Changes in Multiple Sclerosis (MS) Condition". To measure the effectiveness of a Remote Patient Monitoring solution based on the use of a smart insole wearable device (and associated smart phone app), for monitoring MS patients' condition on a day-to-day basis. The main focus is the objective measurement of gait, given that 75% of people with MS...
What is the current status of trial NCT05781113?
This trial is currently active not recruiting. The enrollment target is 90 participants. The study started on 2023-07-01. Estimated completion is 2026-12-31.
What conditions does trial NCT05781113 study?
This clinical trial studies the following conditions: Multiple Sclerosis.
Who is sponsoring clinical trial NCT05781113?
This trial is sponsored by Celestra Health Systems, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05781113 being conducted?
This trial has 3 study locations across Massachusetts, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05781113's enrollment target sits among peer trials
90 137th of 315 higher than 177 of 315 other Multiple Sclerosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
Prepare the Mind: Can Coaching in Goal-directed Behaviour Increase the Success of Cognitive Rehabilitation in People With MS?
RECRUITING · NA
-
Incremental Vestibulo-ocular Reflex Adaptation as a Novel Treatment for Dizziness in People With Multiple Sclerosis
RECRUITING · NA
-
Vancomycin Study in Multiple Sclerosis (MS)
RECRUITING · Phase 1
-
IConquerMS™ - a Patient-Powered Research Network for Multiple Sclerosis
RECRUITING
-
Prospective Investigation of Multiple Sclerosis in the Three Rivers Region
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI